US and European Regulators Approve Trodelvy as First-Line Treatment for Triple-Negative Breast Cancer

The US Food and Drug Administration and the European Medicines Agency have jointly ushered in a new era for breast cancer treatment, approving the targeted therapy Trodelvy for the first-line treatment of metastatic triple-negative breast cancer (TNBC). The consecutive regulatory clearances, issued on June 23 and 24, 2026, elevate the antibody-drug conjugate from a fallback option to a primary weapon against the disease's most aggressive form. For patients facing a diagnosis that has historically offered few effective treatments, the approvals represent a profound shift in the standard of care, allowing oncologists to deploy their most potent therapies before the cancer has a chance to mutate and spread further.[1][4]

Triple-negative breast cancer accounts for roughly 10 to 20 percent of all breast cancer diagnoses, but it is responsible for a disproportionate share of fatalities. The disease earns its name because its cells lack estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) amplifications. Because it lacks these three common biological targets, TNBC is entirely unresponsive to the highly effective hormone therapies and HER2-targeted drugs that have dramatically improved survival rates for other types of breast cancer. Consequently, the five-year survival rate for metastatic TNBC sits at a grim 12 percent, compared to 28 percent for other metastatic breast cancers.[2][7]

The significance of moving Trodelvy to the "first-line" setting—meaning it is the very first systemic treatment a patient receives after a metastatic diagnosis—cannot be overstated by clinical oncologists. Because metastatic TNBC is so relentlessly aggressive, patients often experience a rapid decline in their physical health. Data shows that more than 50 percent of patients who receive standard first-line chemotherapy never become healthy enough to receive a second round of treatment. By authorizing Trodelvy for immediate use, regulators are ensuring that patients receive a highly effective targeted therapy while their bodies are still strong enough to tolerate it.[2][7]

Trodelvy, chemically known as sacituzumab govitecan-hziy, belongs to a revolutionary class of treatments called antibody-drug conjugates (ADCs). Oncologists frequently describe ADCs as "smart bombs" because of their dual-action mechanism. The drug consists of a tumor-seeking antibody linked to a highly potent chemotherapy payload. The antibody specifically hunts for TROP-2, a protein that is heavily overexpressed on the surface of TNBC cells. Once the antibody binds to the TROP-2 receptor, it is absorbed into the cancer cell and releases the toxic chemotherapy directly inside, destroying the tumor while sparing much of the surrounding healthy tissue that traditional systemic chemotherapy would otherwise damage.[2][7]

The FDA's June 2026 decision actually encompasses two distinct first-line indications, giving oncologists unprecedented flexibility. The first approval authorizes Trodelvy as a standalone monotherapy for patients who are not candidates for immunotherapy. The second, broader indication allows Trodelvy to be administered in combination with Merck's blockbuster immunotherapy drug Keytruda (pembrolizumab). This combination is specifically approved for patients whose tumors test positive for the PD-L1 protein, a biomarker that indicates the cancer is using a specific molecular shield to hide from the body's immune system.[1][6]

The monotherapy approval was anchored by the results of the ASCENT-03 clinical trial, a massive international study involving 558 patients with advanced TNBC. The data revealed a stark contrast between the targeted therapy and standard care. Patients receiving Trodelvy experienced a median progression-free survival of 9.7 months, compared to just 6.9 months for those subjected to standard chemotherapy regimens like paclitaxel or gemcitabine. Overall, the ADC reduced the risk of disease progression or death by 38 percent. Furthermore, exactly half of the patients on Trodelvy saw their tumors measurably shrink or disappear, compared to 47 percent on standard chemotherapy.[5][8]

For patients eligible for immunotherapy, the ASCENT-04 trial demonstrated the immense power of combining an ADC with an immune checkpoint inhibitor. In a study of 443 patients with PD-L1 positive tumors, the combination of Trodelvy and Keytruda extended median progression-free survival to 11.2 months, significantly outperforming the 7.8 months achieved by patients receiving standard chemotherapy alongside Keytruda. This dual-pronged attack—using Trodelvy to poison the cancer cells from the inside while Keytruda strips away their immune-evading shields—resulted in a 35 percent reduction in the risk of disease progression or death.[4][5]

The dual approvals intensify a fierce pharmaceutical rivalry in the lucrative antibody-drug conjugate sector. Just one month prior, in May 2026, the FDA approved a competing TROP-2 directed ADC called Datroway, developed jointly by AstraZeneca and Daiichi Sankyo. However, Datroway's first-line TNBC approval was limited strictly to patients who are ineligible for checkpoint inhibitor therapies. By securing a label expansion that explicitly includes combination therapy with Keytruda, Gilead Sciences has positioned Trodelvy to capture a significantly larger share of the first-line market, setting the stage for a high-stakes commercial battle.[3][4]

Despite its targeted nature, Trodelvy is not without severe risks, and its administration requires vigilant oversight by specialized oncology teams. The FDA has mandated a boxed warning—the agency's most stringent safety alert—highlighting the risks of severe diarrhea and neutropenia, a condition characterized by dangerously low white blood cell counts that leaves patients highly vulnerable to life-threatening infections. Patients receiving the drug via intravenous infusion on days one and eight of a 21-day cycle must be closely monitored, and treatment may need to be paused or dose-adjusted if toxicity becomes unmanageable.[1][8]

The rapid, synchronized approval of Trodelvy across multiple international jurisdictions was facilitated by Project Orbis, an initiative led by the FDA's Oncology Center of Excellence that allows for concurrent submission and review of oncology drugs among global partners. As antibody-drug conjugates continue to rewrite the rules of cancer treatment, the swift regulatory action ensures that thousands of patients facing one of the most daunting diagnoses in medicine will not have to wait for the bureaucratic machinery to catch up with the science.[5][8]